Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients wsiltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsiltv.com Daily Mail and Mail on Sunday newspapers.
Longer follow-up data for 1-year transfusion independence in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy
Strong. | May 11, 2023